Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01677858 · ClinicalTrials.gov registry record · Phase 1
A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma
A Phase 1 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 116
- Enrollment target
NCT01677858 is a Phase 1 study that has completed, run by Amgen. The registered enrollment target is 116 participants.
The verdict
NCT01677858, a Phase 1 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 116 participants
- Enrollment target
Study Summary
The study had the following primary objectives: * Phase 1: to determine the maximum tolerated dose (MTD) of once-weekly (QW) carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior therapies * Phase 2: to estimate the overall response rate (ORR) for patients with relapsed or refractory multiple myeloma who received 1 to 3 prior therapies treated with carfilzomib and dexamethasone QW at the MTD established in phase 1.
Interventions
- DRUG Dexamethasone
- DRUG Carfilzomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2012-07-04 |
| Est. Completion | 2018-10-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01677858
The ClinicalTrials.gov registry entry for NCT01677858 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 116 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dexamethasone is the first listed.
NCT01677858 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01677858 about?
NCT01677858 is a clinical study titled "A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma". The study had the following primary objectives: * Phase 1: to determine the maximum tolerated dose (MTD) of once-weekly (QW) carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior therapies * Phase 2: to estimate the overall response r...
What is the current status of trial NCT01677858?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 116 participants. The study started on 2012-07-04. Estimated completion is 2018-10-31.
What interventions are being tested in trial NCT01677858?
The interventions under investigation include: Dexamethasone (DRUG), Carfilzomib (DRUG).
Who is sponsoring clinical trial NCT01677858?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.